Correction to: *Scientific Reports* 10.1038/s41598-018-27461-7, published online 15 June 2018

This Article contains errors.

In Table 1, the fourth column "Gene bank No."

should read:

"Accession No."

Additionally, row Gapdh is incorrect,

"5′-TGACGACTTCAACAGCAACTC-3"

should read:

"5′-TGCGACTTCAACAGCAACTC-3"

"5′-ATGTAGGCCAATGAGGTCCAC-3′"

should read:

"5′-ATGTAGGCCATGAGGTCCAC-3′"

"BC096590"

should read:

"NM_008084"

The Accession No. for *CaSR*,

"NM_013803.3"

should read:

"NM_013803"

Furthermore, in the Discussion section,

"However, it is reasonable to suppose that topical application during vital pulp therapy may pose a much lower risk of side effects compared to systemic application^32,37,51,52^; *in vivo* studies using rat models reported that systemic use of SrRn (625 g/kg) is well tolerated and safe with no adverse side effects^53,54^."

should read:

"However, it is reasonable to suppose that topical application during vital pulp therapy may pose a much lower risk of side effects compared to systemic application^32,37,51,52^; *in vivo* studies using rat models reported that systemic use of SrRn (625 mg/kg) is well tolerated and safe with no adverse side effects^53,54^."
